Cargando…

A molecular case report: Functional assay of tyrosine kinase inhibitors in cells from a patient’s primary renal cell carcinoma

Current therapies for Renal Cell Carcinoma favor vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase (TK) inhibitors (TKIs). In theory, these are most applicable in tumors that have lost VHL-with subsequent stabilization of HIF and upregulation of VEGF. A subset of patients harbor p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kulesz-Martin, Molly, Lagowski, James, Olson, Susan, Wortham, Aaron, West, Toni, Thomas, George, Ryan, Christopher W., Tyner, Jeffrey W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572006/ https://www.ncbi.nlm.nih.gov/pubmed/23192268 http://dx.doi.org/10.4161/cbt.22960

Ejemplares similares

Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models
por: Ouyang, Xiaoming, et al.
Publicado: (2018)

NF-κB Repression by PIAS3 Mediated RelA SUMOylation
por: Liu, Yuangang, et al.
Publicado: (2012)

Biomarkers for tyrosine kinase inhibitors in renal cell cancer
por: Coupe, Nicholas, et al.
Publicado: (2012)

Role(s) of IL-2 inducible T cell kinase and Bruton's tyrosine kinase in mast cell response to lipopolysaccharide
por: Huang, Weishan, et al.
Publicado: (2016)

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines
por: Pleyer, Christopher, et al.
Publicado: (2021)

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
por: Wada, Yoshihiro, et al.
Publicado: (2012)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)

Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
por: Zhang, Hailiang, et al.
Publicado: (2023)

Protein tyrosine kinase 6 regulates activation of SRC kinase
por: Alwanian, Wanian M., et al.
Publicado: (2022)

Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
por: Tullemans, Bibian M. E., et al.
Publicado: (2018)

Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma
por: Sekino, Yohei, et al.
Publicado: (2022)

Protein Tyrosine Kinase 6 Protects Cells from Anoikis by Directly Phosphorylating Focal Adhesion Kinase and Activating AKT
por: Zheng, Yu, et al.
Publicado: (2012)

Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
por: Bukowski, Ronald M.
Publicado: (2012)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?
por: Michaelis, Jakob, et al.
Publicado: (2022)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation
por: Chougule, Rohit A., et al.
Publicado: (2019)

Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors
por: Tahiri, Andliena, et al.
Publicado: (2022)

The Src Family Tyrosine Kinase Fyn Regulates Natural Killer T Cell Development
por: Gadue, Paul, et al.
Publicado: (1999)

Protein Tyrosine Kinase 6 Regulates UVB Induced Signaling and Tumorigenesis in Mouse Skin
por: Chastkofsky, Michael, et al.
Publicado: (2015)

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2016)

Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
por: Aparicio, L. M. A., et al.
Publicado: (2017)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
por: Wu, Jialu, et al.
Publicado: (2020)

Inhibition of T Cell Receptor Signal Transduction by Tyrosine Kinase–interacting Protein of Herpesvirus saimiri
por: Cho, Nam-Hyuk, et al.
Publicado: (2004)

Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib
por: Vigoda, Myles, et al.
Publicado: (2022)

Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors
por: Chung, Shin Hyuck, et al.
Publicado: (2020)

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in  Clear - Cell Renal Cell Carcinoma (ccRCC)
por: Bielecka, Zofia F., et al.
Publicado: (2013)

Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts
por: Bossé, Dominick, et al.
Publicado: (2020)

First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells
por: Hojjat-Farsangi, M., et al.
Publicado: (2018)

The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors
por: Zhang, Haoran, et al.
Publicado: (2020)

Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
por: Park, Hyung Kyu, et al.
Publicado: (2017)

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2022)

The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma
por: Zhuang, Jintao, et al.
Publicado: (2014)

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
por: Beuselinck, B, et al.
Publicado: (2012)

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2017)

Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations
por: Wang, Kun, et al.
Publicado: (2023)

Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse
por: Peng, M, et al.
Publicado: (2015)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
por: Ryan, John J.
Publicado: (2016)

Identification of the Brucea javanica Constituent Brusatol as a EGFR-Tyrosine Kinase Inhibitor in a Cell-Free Assay
por: Suwattanasophon, Chonticha, et al.
Publicado: (2023)

Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models
por: Peng, M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n01a769665tqpqo79j39f4cchm